Rezolute, Inc.
Developing therapies for rare metabolic diseases, focusing on hyperinsulinism-caused hypoglycemia.
RZLT | NDAQ
Overview
Corporate Details
- ISIN(s):
- US76200L3096
- LEI:
- Country:
- United States of America
- Address:
- 275 SHORELINE DRIVE, SUITE 500, 94065 REDWOOD CITY
- Website:
- https://www.rezolutebio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Rezolute, Inc. is a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare and metabolic diseases with serious unmet needs. The company's primary focus is on treating hypoglycemia caused by hyperinsulinism (HI), a condition of excessive insulin secretion. Rezolute's development pipeline targets various forms of the disease, including congenital hyperinsulinism (HI) in infants and children, as well as tumor-induced hyperinsulinism in adults. The company is committed to improving outcomes for patients by addressing the underlying causes of these debilitating conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Rezolute, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Rezolute, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Rezolute, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
